文献速递前列腺癌

三重示踪剂策略对抗转移性前列腺癌(3TMPO)研究方案

The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
PubMed 文献 · BJU Int · 2021-11-11

3TMPO为多中心观察性前瞻临床研究,拟纳入100例来自五家加拿大学术中心的mCRPC患者,采用18F-FDG、68Ga-PSMA-617和68Ga-DOTATATE三重PET/CT评估患者内转移灶间异质性及神经内分泌分化,并评估基于PSMA或DOTATATE的放射配体治疗资格。

要点

  • 三重PET/CT可全身评估mCRPC转移灶间异质性及神经内分泌转分化。
  • PSMA阴性/FDG阳性病灶触发额外68Ga-DOTATATE PET/CT。
  • 基于PSMA或DOTATATE PET阳性评估放射配体治疗资格。

核心结论

  • 三重示踪剂PET/CT策略将无创检测转移灶间异质性和向神经内分泌前列腺癌的转分化,以进一步个体化mCRPC患者诊疗。

研究设计与样本

  • 多中心观察性前瞻临床研究,计划纳入100例来自五家加拿大学术中心的mCRPC患者。
  • 入组条件为影像学或生化进展且常规影像显示至少三处转移。

关键数值与推荐

  • 三重示踪剂包括18F-FDG、68Ga-PSMA-617和68Ga-DOTATATE,分别为葡萄糖类似物、PSMA受体配体和生长抑素受体配体。
  • 先完成68Ga-PSMA-617和18F-FDG PET/CT;若观察到至少一个PSMA阴性/FDG阳性病灶,则追加68Ga-DOTATATE PET/CT。
  • 病灶摄取不一致者视为转移灶间异质性疾病,可考虑活检。
  • 基于68Ga-PSMA-617或68Ga-DOTATATE PET阳性评估PSMA和DOTATATE放射配体治疗资格。

临床怎么用

  • 对mCRPC患者行三重PET/CT全身表征,识别转移灶间异质性及神经内分泌转分化。
  • 根据PSMA或DOTATATE PET阳性结果评估放射配体治疗潜在资格。
  • 将分子影像与活检结果对比,把转移生物学与影像组学特征关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the prevalence of intra-patient inter-metastatic heterogeneity based on positron emission tomography (PET)/computed tomography (CT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and to determine the prevalence of neuroendocrine disease in these patients and their eligibility for radioligand therapies (RLTs). PATIENTS AND METHODS: This multicentre observational prospective clinical study will include 100 patients with mCRPC from five Canadian academic centres. Patients with radiological or biochemical progression and harbouring at least three metastases by conventional imaging will be accrued. Intra-patient inter-metastatic heterogeneity will be determined with triple-tracer imaging using fluorine-18 fluorodeoxyglucose (18 F-FDG), gallium-68-(68 Ga)-prostate-specific membrane antigen (PSMA)-617 and 68 Ga-DOTATATE, which are a glucose analogue, a PSMA receptor ligand and a somatostatin receptor ligand, respectively. The 68 Ga-PSMA-617 and 18 F-FDG PET/CT scans will be performed first. If at least one PSMA-negative/FDG-positive lesion is observed, an additional PET/CT scan with 68 Ga-DOTATATE will be performed. The tracer uptake of individual lesions will be assessed for each PET tracer and patients with lesions presenting discordant uptake profiles will be considered as having inter-metastatic heterogeneous disease and may be offered a biopsy. EXPECTED RESULTS: The proposed triple-tracer approach will allow whole-body mCRPC characterisation, investigating the inter-metastatic heterogeneity in order to better understand the phenotypic plasticity of prostate cancer, including the neuroendocrine transdifferentiation that occurs during mCRPC progression. Based on 68 Ga-PSMA-617 or 68 Ga-DOTATATE PET positivity, the potential eligibility of patients for PSMA and DOTATATE-based RLT will be assessed. Non-invasive whole-body determination of mCRPC heterogeneity and transdifferentiation is highly innovative and might establish the basis for new therapeutic strategies. Comparison of molecular imaging findings with biopsies will also link metastasis biology to radiomic features. CONCLUSION: This study will add novel, biologically relevant dimensions to molecular imaging: the non-invasive detection of inter-metastatic heterogeneity and transdifferentiation to neuroendocrine prostate cancer by using a multi-tracer PET/CT strategy to further personalise the care of patients with mCRPC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Pouliot F, Beauregard JM, Saad F, et al. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. BJU Int. 2021. PMID: 34674367. doi:10.1111/bju.15621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。